- Home
- VIGL vs KPTI Comparison
VIGL vs KPTI Comparison
Compare VIGL & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- KPTI
- Stock Information
- Founded
- VIGL 2020
- KPTI 2008
- Country
- VIGL United States
- KPTI United States
- Employees
- VIGL N/A
- KPTI N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- VIGL Health Care
- KPTI Health Care
- Exchange
- VIGL Nasdaq
- KPTI Nasdaq
- Market Cap
- VIGL 125.3M
- KPTI 121.2M
- IPO Year
- VIGL 2022
- KPTI 2013
- Fundamental
- Price
- VIGL $3.51
- KPTI $0.86
- Analyst Decision
- VIGL Buy
- KPTI Strong Buy
- Analyst Count
- VIGL 5
- KPTI 4
- Target Price
- VIGL $16.60
- KPTI $5.00
- AVG Volume (30 Days)
- VIGL 96.2K
- KPTI 909.8K
- Earning Date
- VIGL 11-05-2024
- KPTI 10-31-2024
- Dividend Yield
- VIGL N/A
- KPTI N/A
- EPS Growth
- VIGL N/A
- KPTI N/A
- EPS
- VIGL N/A
- KPTI N/A
- Revenue
- VIGL N/A
- KPTI $145,668,000.00
- Revenue This Year
- VIGL N/A
- KPTI $6.41
- Revenue Next Year
- VIGL N/A
- KPTI $11.85
- P/E Ratio
- VIGL N/A
- KPTI N/A
- Revenue Growth
- VIGL N/A
- KPTI N/A
- 52 Week Low
- VIGL $2.47
- KPTI $0.62
- 52 Week High
- VIGL $9.24
- KPTI $1.95
- Technical
- Relative Strength Index (RSI)
- VIGL 53.88
- KPTI 58.15
- Support Level
- VIGL $3.30
- KPTI $0.82
- Resistance Level
- VIGL $3.60
- KPTI $0.94
- Average True Range (ATR)
- VIGL 0.16
- KPTI 0.07
- MACD
- VIGL 0.02
- KPTI 0.01
- Stochastic Oscillator
- VIGL 81.63
- KPTI 68.90
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.